Loading…
Responsibility in Drug Advertising Act of 2017
Legislative Progress
Introduced
November 14, 2017
Latest Action
November 17, 2017
Primary Sponsor
Rosa L. DeLauroDemocratic(CT)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
46pct
3d open
vs 7,393 other HR bills in the 115th — cohort avg 50d
Responsibility in Drug Advertising Act of 2017 This bill amends the Federal Food, Drug, and Cosmetic Act to prohibit direct-to-consumer advertising of a drug in the first three years after the drug's approval. The Food and Drug Administration may: (1) waive the third year of this prohibition for a drug if direct-to-consumer advertising of the drug would have an affirmative value to public health, or (2) extend the prohibition if the drug has significant adverse health effects.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2018 · fourth_quarter · Pharmacy
Proposals relating to the regulation of direct-to-consumer prescription drug advertising H.R. 4385, Responsibility in Drug Advertising Act of 2017, which would prohibit DTC advertising of prescription drugs for the first three years after FDA approval Amendment to Labor-HHS appropriations bill and in omnibus appropriations bill (H.R. 6157) to require drug companies to list price information in direct-to-consumer prescription drug advertising Comments to the Centers for Medicare & Medicaid Services on proposed requirement that direct-to-consumer television ads of prescription drugs and biological products payable under Medicare or Medicaid must include the product's "Wholesale Acquisition Cost" in the ad.
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $480,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Federal Communications Commission (FCC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
2018 · fourth_quarter · Advertising
H.R.1776/ S.771, Improving Access To Affordable Prescription Drugs Act H.R. 2439/ S.1131, Fair Accountability and Innovative Research Drug Pricing Act S.1348, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act H.R.4385, Responsibility in Drug Advertising Act H.R.4116, Transparent Drug Pricing Act S.2157, Drug-Price Transparency in Communications Act S.2478, End Taxpayer Subsidies for Drug Ads Act FTC Reauthorization Act of 2018 (Not introduced)
Client expense: Not reported · Firm income: $90,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Pharmacy
Proposals relating to the regulation of direct-to-consumer prescription drug advertising H.R. 4385, Responsibility in Drug Advertising Act of 2017, which would prohibit DTC advertising of prescription drugs for the first three years after FDA approval Amendment to Labor-HHS appropriations bill and in omnibus appropriations bill (H.R. 6157) to require drug companies to list price information in direct-to-consumer prescription drug advertising
Client expense: $430,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Federal Communications Commission (FCC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Natl Telecommunications & Information Administration (NTIA), SENATE, Treasury, Dept of
2018 · third_quarter · Advertising
H.R.1776/ S.771, Improving Access To Affordable Prescription Drugs Act H.R. 2439/ S.1131, Fair Accountability and Innovative Research Drug Pricing Act S.1348, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act H.R.4385, Responsibility in Drug Advertising Act H.R.4116, Transparent Drug Pricing Act S.2157, Drug-Price Transparency in Communications Act S.2478, End Taxpayer Subsidies for Drug Ads Act FTC Reauthorization Act of 2018 (Not introduced)
Client expense: Not reported · Firm income: $90,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Pharmacy
Proposals relating to the regulation of direct-to-consumer prescription drug advertising H.R. 4385, Responsibility in Drug Advertising Act of 2017, which would prohibit DTC advertising of prescription drugs for the first three years after FDA approval
Client expense: $420,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE, State, Dept of (DOS), Treasury, Dept of
2018 · second_quarter · Advertising
H.R.1776/ S.771, Improving Access To Affordable Prescription Drugs Act H.R. 2439/ S.1131, Fair Accountability and Innovative Research Drug Pricing Act S.1348, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act H.R.4385, Responsibility in Drug Advertising Act H.R.4116, Transparent Drug Pricing Act S.2157, Drug-Price Transparency in Communications Act S.2478, End Taxpayer Subsidies for Drug Ads Act FTC Reauthorization Act of 2018 (Not introduced)
Client expense: Not reported · Firm income: $210,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · first_quarter · Pharmacy
Proposals relating to the regulation of direct-to-consumer prescription drug advertising H.R. 4385, Responsibility in Drug Advertising Act of 2017, which would prohibit DTC advertising of prescription drugs for the first three years after FDA approval
Client expense: $440,000 · Firm income: Not reported
Government targets: Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE, Treasury, Dept of
2018 · first_quarter · Advertising
H.R.1776/ S.771, Improving Access To Affordable Prescription Drugs Act H.R. 2439/ S.1131, Fair Accountability and Innovative Research Drug Pricing Act S.1348, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act H.R.4385, Responsibility in Drug Advertising Act H.R.4116, Transparent Drug Pricing Act S.2157, Drug-Price Transparency in Communications Act S.2478, End Taxpayer Subsidies for Drug Ads Act FTC Reauthorization Act of 2018 (Not introduced)
Client expense: Not reported · Firm income: $240,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · fourth_quarter · Pharmacy
Proposals relating to the regulation of direct-to-consumer prescription drug advertising H.R. 4385, Responsibility in Drug Advertising Act of 2017, which would prohibit DTC advertising of prescription drugs for the first three years after FDA approval
Client expense: $450,000 · Firm income: Not reported
Government targets: Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE, Treasury, Dept of
2017 · fourth_quarter · Advertising
H.R. 1, An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018 H.R.1776/ S.771, Improving Access To Affordable Prescription Drugs Act H.R. 2439/ S.1131, Fair Accountability and Innovative Research Drug Pricing Act S.1348, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act H.R.4385, Responsibility in Drug Advertising Act H.R.4116, Transparent Drug Pricing Act S.2157, Drug-Price Transparency in Communications Act FTC Reauthorization Act of 2017 (Not introduced)
Client expense: Not reported · Firm income: $110,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE